Alexander Kuhn1, Jean Park1, Adline Ghazi1, Vanita R Aroda2,3. 1. MedStar Health Research Institute, 6525 Belcrest Road, Suite #700, Hyattsville, MD, 20782, USA. 2. MedStar Health Research Institute, 6525 Belcrest Road, Suite #700, Hyattsville, MD, 20782, USA. vanita.aroda@medstar.net. 3. Georgetown University School of Medicine, Washington, DC, USA. vanita.aroda@medstar.net.
Abstract
PURPOSE OF REVIEW: Guidelines for a standard second diabetes medication for the treatment of type 2 diabetes (T2DM) have yet to be established. The rapid increase in the number of newer therapies available makes the choice more difficult. Thus, we reviewed clinical trial evidence evaluating newer therapies available for treatment intensification beyond monotherapy. RECENT FINDINGS: Head-to-head studies comparing newer therapies versus traditional (i.e., sulfonylurea) approaches consistently find lower incidence of hypoglycemia and weight gain with newer therapies. Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors demonstrate high glycemic efficacy, while merits of dipeptidyl peptidase-4 (DPP-4) inhibitors include their tolerability. Secondary effects (weight loss, cardiovascular outcomes, renal function) are of growing interest with newer therapies. Choices for treatment intensification in T2DM diabetes are numerous. Understanding the comparative evidence of newer treatment choices, as provided in this review, may help guide clinical decision making.
PURPOSE OF REVIEW: Guidelines for a standard second diabetes medication for the treatment of type 2 diabetes (T2DM) have yet to be established. The rapid increase in the number of newer therapies available makes the choice more difficult. Thus, we reviewed clinical trial evidence evaluating newer therapies available for treatment intensification beyond monotherapy. RECENT FINDINGS: Head-to-head studies comparing newer therapies versus traditional (i.e., sulfonylurea) approaches consistently find lower incidence of hypoglycemia and weight gain with newer therapies. Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors demonstrate high glycemic efficacy, while merits of dipeptidyl peptidase-4 (DPP-4) inhibitors include their tolerability. Secondary effects (weight loss, cardiovascular outcomes, renal function) are of growing interest with newer therapies. Choices for treatment intensification in T2DM diabetes are numerous. Understanding the comparative evidence of newer treatment choices, as provided in this review, may help guide clinical decision making.
Entities:
Keywords:
DPP-4 inhibitors; GLP-1 receptor agonists; Intensification after monotherapy; SGLT-2 inhibitors; Type 2 diabetes
Authors: Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz Journal: N Engl J Med Date: 2013-09-02 Impact factor: 91.245
Authors: Baptist Gallwitz; Julio Rosenstock; Thomas Rauch; Sudipta Bhattacharya; Sanjay Patel; Maximilian von Eynatten; Klaus A Dugi; Hans-Juergen Woerle Journal: Lancet Date: 2012-06-28 Impact factor: 79.321
Authors: John B Buse; Michael Nauck; Thomas Forst; Wayne H-H Sheu; Sylvia K Shenouda; Cory R Heilmann; Byron J Hoogwerf; Aijun Gao; Marilyn K Boardman; Mark Fineman; Lisa Porter; Guntram Schernthaner Journal: Lancet Date: 2012-11-07 Impact factor: 79.321
Authors: F J Lavalle-González; A Januszewicz; J Davidson; C Tong; R Qiu; W Canovatchel; G Meininger Journal: Diabetologia Date: 2013-09-13 Impact factor: 10.122
Authors: Ralph A DeFronzo; Miguel N Hissa; Alan J Garber; Jorge Luiz Gross; Raina Yuyan Duan; Shoba Ravichandran; Roland S Chen Journal: Diabetes Care Date: 2009-05-28 Impact factor: 19.112
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: A Philis-Tsimikas; S Del Prato; I Satman; A Bhargava; M Dharmalingam; T V Skjøth; S Rasmussen; A J Garber Journal: Diabetes Obes Metab Date: 2013-05-06 Impact factor: 6.577